May Wang, Ph.D., is a Senior Scientist and member of the original founding team at Skylark Bio, where she drives the design and delivery of innovative gene therapies to transform patient lives. Since the company’s establishment in February 2021, she has been instrumental in building its internal AAV capabilities, leading everything from vector design and production to in vitro assay development. Dr. Wang currently focuses on CMC manufacturing (process/assay development and supply chain logistics) and novel AAV vector development, working within multidisciplinary cross-functional teams. Previously, she established AAV capabilities at Ally Therapeutics. She earned her Ph.D. in Virology from Harvard Medical School and her Bachelor’s in Biochemistry from Tufts University.